about
Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocolsDNA topoisomerase IIα and Ki67 are prognostic factors in patients with hepatocellular carcinoma.Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies.Visual detection of serum asialohaptoglobin by plasmonic sandwich ELLSA--a new platform for cirrhosis diagnosis.XRCC1 and XPD polymorphisms and their relation to the clinical course in hepatocarcinoma patients.5H-benzo[h]thiazolo[2,3-b]quinazolines ameliorate NDEA-induced hepatocellular carcinogenesis in rats through IL-6 downregulation along with oxidative and metabolic stress reduction.Stage of disease in hepatitis B virus infection in Zambian adults is associated with large cell change but not well defined using classic biomarkers.miRNA-223-3p regulates NLRP3 to promote apoptosis and inhibit proliferation of hep3B cells.Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma.Aflatoxin B1 exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption.Decreased expression of microRNA-223 promotes cell proliferation in hepatocellular carcinoma cells via the insulin-like growth factor-1 signaling pathway.Editorial: charting the future of hepatocellular carcinoma publications.Clinical utility of decarboxylation prothrombin combined with α-fetoprotein for diagnosing primary hepatocellular carcinomaYoung Adult Cancer: Influence of the Obesity PandemicTranscriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology
P2860
Q26783881-57DD10AD-DBB1-4283-A6E7-8235C2841CDEQ33751222-489C9900-2C39-4FF7-9E05-91874D15172DQ39458547-79C0BDBA-9B56-4C3E-ADFB-FF67F567872DQ41123248-F7B6E52D-E3F6-439D-BE78-1637C9DFE354Q41614044-DF4AF212-D2A2-4A24-B889-8930EC7B3C69Q42673174-2C3442E2-04B6-4F6F-B347-1ADA6C008CEEQ47548262-B88C247F-AFFF-45F4-A18E-AD316F09135EQ50248848-AF691F2D-A7A3-49C7-A8DF-6A8E74DB54AEQ52355121-BFCEC134-B89D-4268-A871-A3C8D7EC27FAQ52658108-43B59C22-2794-48F3-8D9A-ADA212105D8AQ54090322-2D1A6C60-452A-403F-916B-B391C85AF701Q55194918-38DF0CCD-697C-46B6-A7AB-A5C80111A738Q57021120-DCC58795-FFA6-41EA-8653-646EF91C102DQ57094794-877B2AE2-3565-4E09-853E-07E68456B8A9Q59129137-EE8E3DDD-BE3C-406F-BC2E-8C89C65464B5
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 August 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatocellular carcinoma: epidemiology and risk factors
@en
Hepatocellular carcinoma: epidemiology and risk factors.
@nl
type
label
Hepatocellular carcinoma: epidemiology and risk factors
@en
Hepatocellular carcinoma: epidemiology and risk factors.
@nl
prefLabel
Hepatocellular carcinoma: epidemiology and risk factors
@en
Hepatocellular carcinoma: epidemiology and risk factors.
@nl
P2860
P356
P1476
Hepatocellular carcinoma: epidemiology and risk factors
@en
P2093
Michael C Kew
P2860
P304
P356
10.2147/JHC.S44381
P577
2014-08-13T00:00:00Z